In the US,<unk>  is indicated to treat patients whose cancers are ROS1-positive (have a specific genetic feature (biomarker)). It is to be used in those with solid tumors that:<unk>  is not approved for use in those less than twelve years of age. In the European Union,<unk>  as monotherapy is indicated for the treatment of adults and adolescents twelve years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, * who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and * who have not received a prior NTRK inhibitor * who have no satisfactory treatment options. It is also indicated for the treatment of adults with ROS1 positive, advanced non small cell lung cancer (NSCLC) not previously treated with ROS1 inhibitors.
Entrectinib
Dabrafenib
Neratinib
Selpercatinib
Tucatinib
Baricitinib
Fostamatinib
Encorafenib